-
Je něco špatně v tomto záznamu ?
Monitoring of Lymphocyte Populations During Treatment with Interferon-β-1b to Predict Multiple Sclerosis Disability Progression
M. Vališ, O. Vyšata, L. Sobíšek, B. Klímová, C. Andrýs, D. Vokurková, Z. Pavelek,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
30592627
DOI
10.1089/jir.2018.0100
Knihovny.cz E-zdroje
- MeSH
- dospělí MeSH
- interferon beta terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- lymfocyty patologie MeSH
- mladý dospělý MeSH
- počet lymfocytů MeSH
- roztroušená skleróza krev farmakoterapie MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
The authors aim to understand how lymphocyte populations could predict the course of multiple sclerosis (MS) in people treated with interferon-β (IFN-β). Twenty-five male patients and 72 female patients were analyzed in the study. Peripheral blood samples were taken before and 5 years after the treatment with IFN-β. Lymphocyte subsets were analyzed by flow cytometry. The authors compared lymphocyte parameters between confirmed sustained progression (CSP) and non-CSP groups by using Welch's one-way analysis of means or a chi-square test of independence. A penalized (lasso) logistic regression model was fitted to identify the combination of lymphocyte parameters for potential biomarkers. The combination of lymphocyte counts, relative CD3+/CD25+ cells, absolute CD8 T cells, absolute CD8+/CD38+ cells, absolute CD38+ cells, and relative CD5+/CD19+ cells was identified as potential biomarker for the IFN-β treatment to monitor MS development in relation to CSP. The results suggest that other biomarkers aid in patient observation, predict a favorable outcome, and assist in the decision-making process for the early therapy escalation.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20022865
- 003
- CZ-PrNML
- 005
- 20220103092753.0
- 007
- ta
- 008
- 201125s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1089/jir.2018.0100 $2 doi
- 035 __
- $a (PubMed)30592627
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Vališ, Martin $u 1 Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague , Hradec Králové, Czech Republic .
- 245 10
- $a Monitoring of Lymphocyte Populations During Treatment with Interferon-β-1b to Predict Multiple Sclerosis Disability Progression / $c M. Vališ, O. Vyšata, L. Sobíšek, B. Klímová, C. Andrýs, D. Vokurková, Z. Pavelek,
- 520 9_
- $a The authors aim to understand how lymphocyte populations could predict the course of multiple sclerosis (MS) in people treated with interferon-β (IFN-β). Twenty-five male patients and 72 female patients were analyzed in the study. Peripheral blood samples were taken before and 5 years after the treatment with IFN-β. Lymphocyte subsets were analyzed by flow cytometry. The authors compared lymphocyte parameters between confirmed sustained progression (CSP) and non-CSP groups by using Welch's one-way analysis of means or a chi-square test of independence. A penalized (lasso) logistic regression model was fitted to identify the combination of lymphocyte parameters for potential biomarkers. The combination of lymphocyte counts, relative CD3+/CD25+ cells, absolute CD8 T cells, absolute CD8+/CD38+ cells, absolute CD38+ cells, and relative CD5+/CD19+ cells was identified as potential biomarker for the IFN-β treatment to monitor MS development in relation to CSP. The results suggest that other biomarkers aid in patient observation, predict a favorable outcome, and assist in the decision-making process for the early therapy escalation.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a interferon beta $x terapeutické užití $7 D016899
- 650 _2
- $a počet lymfocytů $7 D018655
- 650 _2
- $a lymfocyty $x patologie $7 D008214
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a roztroušená skleróza $x krev $x farmakoterapie $7 D009103
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Vyšata, Oldřich $u 1 Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague , Hradec Králové, Czech Republic .
- 700 1_
- $a Sobíšek, Lukáš, $u 2 Department of Statistics and Probability, University of Economics in Prague , Prague, Czech Republic . $d 1983- $7 xx0238269
- 700 1_
- $a Klímová, Blanka $u 1 Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague , Hradec Králové, Czech Republic .
- 700 1_
- $a Andrýs, Ctirad $u 3 Department of Clinical Immunology and Allergology, University Hospital Hradec Králové , Hradec Králové, Czech Republic .
- 700 1_
- $a Vokurková, Doris $u 3 Department of Clinical Immunology and Allergology, University Hospital Hradec Králové , Hradec Králové, Czech Republic .
- 700 1_
- $a Pavelek, Zbyšek $u 1 Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague , Hradec Králové, Czech Republic .
- 773 0_
- $w MED00002748 $t Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research $x 1557-7465 $g Roč. 39, č. 3 (2019), s. 164-173
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30592627 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20220103092753 $b ABA008
- 999 __
- $a ok $b bmc $g 1595184 $s 1113541
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 39 $c 3 $d 164-173 $e 20181228 $i 1557-7465 $m Journal of interferon & cytokine research $n J Interferon Cytokine Res $x MED00002748
- LZP __
- $a Pubmed-20201125